Chromogranin - A

Overview

  • EPIC Code:
  • IMO95
  • Soft Test Code:
  • CHRGA
  • Send Out Test Code:
  • 31911
Alternate Names
  • CgA
  • Chromogranin-A
Clinical Significance

Chromogranin A, Rebaseline - Chromogranin-A (CgA) is an acidic glycoprotein expressed in the secretory granules of most normal and neoplastic neuroendocrine (NE) cell types, where it is released together with peptide hormones and biogenic amines. Neuroendocrine tumors (NETs) are a form of cancer that differ from other neoplasia in that they synthesize, store, and secrete peptides, e.g., CgA and amines. CgA is secreted from neuroendocrine-derived tumors including foregut, midgut and hindgut gastrointestinal NETs, pheochromocytomas, neuroblastomas, medullary thyroid carcinomas, some pituitary tumors, functioning and non-functioning pancreatic NETs. Significantly elevated CgA levels have been found in patients with other diseases, such as impaired renal function, untreated benign essential hypertension, gastritis, prostatic carcinoma, and hyperparathyroidism. The best-characterized circulating biomarker that identifies NETs in general is CgA. Monitoring blood CgA levels may effectively provide information that is helpful in delineating tumor burden and rate of tumor growth, predicting tumor response to therapy and providing some indication as to prognosis.


Specimen Collection & Preparation

Specimen Requirements

1.0 mL Serum from a Red Top Tube in a Plastic Vial

Alternate Specimen

TransportAndStorage

7 days Ambient

31 days Frozen (Transport)
 
Do not store refrigerated. 

Collection Instructions

Treatment with proton-pump inhibitors or H2-receptor blockers will cause an increase in Chromogranin A concentrations

 
Allow blood to clot at room temperature. Centrifuge and separate the serum from the cells immediately. 

Clinical Interpretation

Reference Range:

Adults: <311 ng/mL


Methodology:
  • Chromatography / Mass Spectrometry

Clinical Significance

Chromogranin A, Rebaseline - Chromogranin-A (CgA) is an acidic glycoprotein expressed in the secretory granules of most normal and neoplastic neuroendocrine (NE) cell types, where it is released together with peptide hormones and biogenic amines. Neuroendocrine tumors (NETs) are a form of cancer that differ from other neoplasia in that they synthesize, store, and secrete peptides, e.g., CgA and amines. CgA is secreted from neuroendocrine-derived tumors including foregut, midgut and hindgut gastrointestinal NETs, pheochromocytomas, neuroblastomas, medullary thyroid carcinomas, some pituitary tumors, functioning and non-functioning pancreatic NETs. Significantly elevated CgA levels have been found in patients with other diseases, such as impaired renal function, untreated benign essential hypertension, gastritis, prostatic carcinoma, and hyperparathyroidism. The best-characterized circulating biomarker that identifies NETs in general is CgA. Monitoring blood CgA levels may effectively provide information that is helpful in delineating tumor burden and rate of tumor growth, predicting tumor response to therapy and providing some indication as to prognosis.


Production Schedule

Sites Performed
  • Quest - Chantilly to San Juan Capistrano
Days Performed
Monday
Tuesday
Wednesday
Thursday
Friday
Saturday
Departments
  • Sendouts - Clinical
Turn Around Time

3 to 5 days


Coding & Compliance

CDM

00914520


CPT Coding

86316